Status:
NOT_YET_RECRUITING
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
Lead Sponsor:
Ruijin Hospital
Conditions:
Acute Leukemia
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adult...
Eligibility Criteria
Inclusion
- Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
- Age: 18-75 years old (including boundary values of 18 and 75);
- Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity
Exclusion
- The subject's previous history of anti-tumor treatment meets one of the following conditions:
- Individuals who have previously received bevacizumab
- Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
- Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06876701
Start Date
April 1 2025
End Date
April 1 2027
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Zhaxin integrated hospital of traditional Chinese and Western Medicine
Shanghai, China